Tracy Warren’s recent co-first author manuscript is now out as a preprint on medRxiv! This collaborative project between the Nord Lab, the Carter Lab at UC Davis Medical Center, and the Sham Lab at the University of Hong Kong, assessed how polygenic risk for schizophrenia that affects different neurotransmitter pathways is associated with different symptom profiles in humans with psychotic disorders. Major findings include that subjects with increased glutamatergic risk variants tended to have more severe cognitive control symptoms, subjects with increased dopaminergic risk were better candidates for antipsychotic medication, and unsupervised clustering on subject phenotypes identified groups that differed primarily by severity of positive symptoms, negative symptoms, and cognitive symptoms. These clusters showed different profiles of genetic risk and different responsiveness to antipsychotic medication.
Check out the preprint here!
Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis | medRxiv
